Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue SUPPL. A, 1997, Pages 73-81

  O'Doherty, Brian ^a   Dutchman, David A ^b   Pettit, Ross ^c   Maroli, Alan ^c  

^a Roebuck House ^*  (United Kingdom)

^b Roebuck House   (United Kingdom)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CREATININE; GREPAFLOXACIN;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PAIN; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STREPTOCOCCUS PNEUMONIAE; SWEATING; SYMPTOM; TASTE DISORDER; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-INFECTIVE AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; HEMATOLOGIC TESTS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PATIENT DROPOUTS; PENICILLINS; PIPERAZINES; PNEUMONIA, BACTERIAL; QUINOLONES; TREATMENT OUTCOME;

EID: 0031446686     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.suppl_1.73     Document Type: Conference Paper

References (21)

1. Research Committee of the British Thoracic Society and Public Health Laboratory Service. (1987). Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. Quarterly Journal of Medicine 62, 195-220.
2. US Department of Commerce. (1988). Statistical Abstract of the United States, edn. 108. Bureau of Census, Washington, DC.
3. Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E. et al. (1977). A prediction rule to identify low-risk patients with community-acquired pneumonia. New England Journal of Medicine 336, 243-50.
4. Meyer, R. D. & Finch, R. G. (1992). Community acquired pneumonia. Journal of Hospital Infection 22, Suppl. A, 51-4.
5. George, R. C., Ball, L. C. & Cooper, P. G. (1992). Antibiotic resistant pneumococci in the United Kingdom. Communicable Diseases Report CDR Review 2, 37-42.
6. Obaro, S. K., Monteil, M. A. & Henderson, D. C. (1996). The pneumococcal problem. British Medical Journal 312, 1521-5.
7. Appelbaum, P. C. (1992). Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clinical Infectious Diseases 15, 77-83.
8. Linares, J., Pallares, R., Alonso, T., Perez, J. L., Ayats, J., Gudiol, F. et at. (1992). Trends in antimicrobial resistance in clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clinical Infectious Diseases 15, 99-105.
9. Neu, H. C. (1992). The crisis in antibiotic resistance. Science 257, 1064-73.
10. Jorgensen, J. H., Doern, G. V., Maher, L. A., Howell, A. W. & Redding, J. S. (1990). Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy 34, 2075-80.
11. Neu, H. C. & Sabath, L. D. (1993). Criteria for selecting oral antibiotic therapy for community-acquired pneumonia. Infections in Medicine 10, Suppl. D, 33-40.
12. Vogel, F. (1995). A guide to the treatment of lower respiratory tract infections. Drugs 50, 62-72.
13. Imada, T., Miyazaki, S., Nishida, M., Yamaguchi, K. & Goto, S. (1992). In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrobial Agents and Chemotherapy 36, 573-9.
14. Sader, H. S., Erwin, M. E. & Jones, R. N. (1992). In vitro antimicrobial activity of OPC-17116 compared to other broad spectrum fluoroquinolones. European Journal of Clinical Microbiology & Infectious Diseases 11, 372-81.
15. Neu, H. C., Fang, W., Gu, J. W. & Chin, N. X. (1992). In vitro activity of OPC-17116. Antimicrobial Agents and Chemotherapy 6, 1310-5.
16. Wise, R., Andrews, J. M. & Brenwald, N. (1993). The in vitro activity of OPC-17116, a new 5-methyl substituted quinolone. Journal of Antimicrobial Chemotherapy 31, 497-504.
17. Child, J., Andrews, M. & Wise, R. (1995). Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrobial Agents and Chemotherapy 39, 513-5.
18. Makuch, R. & Simon, S. (1978). Sample size requirements for evaluating a conservative therapy. Cancer Treatment Reports 62, 1037-40.
19. McCormick, D., Singer, D. E., Coley, C. M. et al. (1996). Variation in length of hospital stay and its relation to medical outcomes in patients with community-acquired pneumonia. Journal of General Internal Medicine 11, Suppl. 80, abstract.
20. Ferguson, J. & Dawe, R. (1997). Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 93-8.
21. Eisen, S. A., Miller, D. K., Woodward, R. S., Spitznagel, E. & Przybeck, T. R. (1990). The effect of prescribed daily dose frequency on patient medication compliance. Archives of Internal Medicine 150, 1881-4.